v3.21.2
Condensed Balance Sheets - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Current assets:    
Cash $ 46,836,556 $ 13,953,513
Grants receivable 586,581  
Prepaid research and development 958,779 774,356
Prepaid expenses and other current assets 833,963 54,837
Total assets 49,215,879 14,782,706
Current liabilities:    
Accounts payable 897,226 1,720,680
Accrued expenses and other current liabilities 872,771 632,934
Deferred revenue 142,619 2,325,741
Notes payable   42,534
Total 1,912,616 4,721,889
Notes payable, net of current portion 248,911 276,461
Total liabilities 2,161,527 4,998,350
Commitments and contingencies (see Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2021, and December 31, 2020; 0 shares issued and outstanding at June 30, 2021, and December 31, 2020
Common stock, $0.001 par value; 100,000,000 and 30,000,000 shares authorized; 25,133,345 and 10,050,849 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively. 25,134 10,051
Additional paid-in capital 67,334,089 24,805,929
Accumulated deficit (20,304,871) (15,031,624)
Total 47,054,352 9,784,356
Total liabilities and stockholders' equity $ 49,215,879 $ 14,782,706

Source